CNN) -- A drug that presents a new way to knock out cancer cells was approved Friday to treat patients with a certain type of late-stage metastatic breast cancer.
The drug, referred to as T-DM1 during clinical research, will now be known by the brand name Kadcyla, the Food and Drug Administration said in its approval announcement. It's a new therapy for women with HER2-positive breast cancer.
Kadcyla is a combination
of the targeted drug trastuzumab -- better known by the brand name
Herceptin -- and a powerful chemotherapy drug called DM1. It's designed
to work when Herceptin alone can no longer keep cancer in check.
DM1 is too toxic to
deliver directly into a patient's bloodstream, like other chemotherapy
drugs. The Herceptin part of the new drug homes in on cancer cells,
sparing other healthy cells, and delivers DM1 into the cell..."
REMEMBER BREAST CANCER IS FOUND IN MANY MEN AS WELL...
No comments:
Post a Comment